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A B S T R A C T
Background: Particularly in the pediatric clinical pharmacology ﬁeld, data-sharing oﬀers the possibility of
making the most of all available data. In this study, we utilize previously collected therapeutic drug monitoring
(TDM) data of term and preterm newborns to develop a population pharmacokinetic model for phenobarbital.
We externally validate the model using prospective phenobarbital data from an ongoing pharmacokinetic study
in preterm neonates.
Methods: TDM data from 53 neonates (gestational age (GA): 37 (24–42) weeks, bodyweight: 2.7 (0.45–4.5) kg;
postnatal age (PNA): 4.5 (0−22) days) contained information on dosage histories, concentration and covariate
data (including birth weight, actual weight, post-natal age (PNA), postmenstrual age, GA, sex, liver and kidney
function, APGAR-score). Model development was carried out using NONMEM® 7.3. After assessment of model ﬁt,
the model was validated using data of 17 neonates included in the DINO (Drug dosage Improvement in
NeOnates)-study.
Results: Modelling of 229 plasma concentrations, ranging from 3.2 to 75.2 mg/L, resulted in a one compartment
model for phenobarbital. Clearance (CL) and volume (Vd) for a child with a birthweight of 2.6 kg at PNA day 4.5
was 0.0091 L/h (9%) and 2.38 L (5%), respectively. Birthweight and PNA were the best predictors for CL
maturation, increasing CL by 36.7% per kg birthweight and 5.3% per postnatal day of living, respectively. The
best predictor for the increase in Vd was actual bodyweight (0.31 L/kg). External validation showed that the
model can adequately predict the pharmacokinetics in a prospective study.
Conclusion: Data-sharing can help to successfully develop and validate population pharmacokinetic models in
neonates. From the results it seems that both PNA and bodyweight are required to guide dosing of phenobarbital
in term and preterm neonates.
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1. Introduction
Rational dosing guidelines for drugs in neonates are urgently
needed. However, datasets from prospective clinical trials in children
are scarce and both the number of included children and the number of
samples per child are usually very small (Knibbe et al., 2011). To
overcome this problem data-sharing is of utmost importance and can
help to make the most out of all available data (Knibbe et al., 2011; Ince
et al., 2009; Knibbe and Danhof, 2011). Existing data can be utilized to
determine the optimal design of prospective trials but it may also aid
dose ﬁnding in ongoing trials in case the collected data is not (yet)
suﬃcient to draw valid conclusions (Ince et al., 2009; Krekels et al.,
2015).
Besides that, the application of advanced data analysis techniques,
namely the population pharmacokinetic modelling approach, allows
handling sparse and infrequently collected samples (Knibbe and
Danhof, 2011). Moreover, it oﬀers the possibility to quantify inter-
individual variability and to identify covariates that determine the
pharmacokinetics of drugs along the whole pediatric life-span and can
thereby be used to optimize drug dosing (Brussee et al., 2016; De Cock
et al., 2011).
Phenobarbital remains the traditional ﬁrst-line treatment for sei-
zures in neonates although evidence to favour one antiepileptic agent
over the other is lacking (Blume et al., 2009). Using phenobarbital
alone, only around 50% of seizures can be eﬀectively controlled
(Painter et al., 1999; Tulloch et al., 2012). As persistence of seizures
might cause permanent functional and structural damage to the brain
and existing brain damage might be worsened (Wirrell et al., 2001;
Rennie and Boylan, 2003), safe and eﬃcacious treatment is of primary
importance. The optimal dosage of phenobarbital in term and preterm
neonates remains a topic of discussion. The therapeutic eﬀect is dose
dependent with a suggested therapeutic range between 15 and 40 mg/L
(Gilman et al., 1989). At higher concentrations sedation and feeding
diﬃculties might occur (Ouvrier and Goldsmith, 1982). The Dutch
National Children's Formulary recommends a loading dose of 20 mg/kg
and a maintenance dose of 2.5–5 mg/kg/day (Dutch National Children's
Formulary, 2016). However, pharmacokinetic data is sparse in term
(Ouvrier and Goldsmith, 1982; Donn et al., 1985; Heimann and
Gladtke, 1977; Marsot et al., 2014; Yukawa et al., 2011) and preterm
(Marsot et al., 2014; Yukawa et al., 2011; Oztekin et al., 2013)
newborns.
In this analysis, we utilize therapeutic drug monitoring (TDM) data
collected between 1997 and 2003 in the neonatal intensive care unit of
the Maastricht University Medical Centre (study 1) to build a popula-
tion pharmacokinetic model for phenobarbital in term and preterm
newborns. We validate the model with data originating from an
ongoing PK study (DINO-study: Drug dosage Improvement in preterm
NeOnates, NL47409.078.14) (study 2). This study collects pharmaco-
kinetic data of phenobarbital and eight other frequently used oﬀ-label
drugs in preterm neonates to increase the knowledge on the pharma-
cokinetics and pharmacodynamics using sparse sampling and limited
sample volumes to minimize the burden on the individual child. Using
this approach, we illustrate that data sharing and external validation
can lead to model-based clinical dose optimization, particularly in
neonates where ethical and practical constraints limit the possibilities
to perform studies.
2. Methods
2.1. Model development dataset (TDM data, study 1)
TDM data (study 1) were obtained from the database of the
Maastricht University Medical Centre between 1997 and 2003 with
approval from the medical ethical committee (MEC 02-204.3).
Neonates younger than 35 days at the start of phenobarbital treatment
were included. A total of 229 samples from 53 neonates (28 male, 25
female) were available for analysis. First dose and consecutive doses
(intravenous as well as oral) varied between 4 and 40.7 mg/kg and 1.3
and 20 mg/kg, respectively, and the study period ranged from 4 to
85 days (Table 1). The median ﬁrst dose was 20 mg/kg, 17 children
received a ﬁrst dose that was higher than 25 mg/kg. The median
maintenance dose was 3.9 mg/kg. Covariates were retrieved from the
patient's records.
2.2. External model validation dataset (prospective data, study 2)
The DINO-study (NL47409.078.14, MEC-2014-067, study 2) pro-
spectively studies a total of nine drugs including phenobarbital used as
standard of care in preterm infants born before 32 weeks of gestation
aiming at evidence-based individualized dosing regimen and is still
ongoing. From September 2014 to September 2016, 61 blood samples
from 17 children (7 female, 10 male) containing phenobarbital were
evaluable for the analysis (Table 1).
2.3. Bioanalytical analysis
Phenobarbital concentrations of the model development dataset
(study 1) were determined using a ﬂuorescence polarization assay
(Steijns et al., 2002) on the COBAS INTEGRA 700 (Roche Diagnostics;
Basel, Switzerland) using COBAS INTEGRA reagent system cassettes at
the pharmacy of Maastricht University Medical Centre. Fluorescein-
labelled phenobarbital binds an antibody and the emitted light is
polarized due to the reduction in freedom of rotation. In case
phenobarbital is present in the patients serum it reduces the extent of
ﬂuorescence polarization due to antibody binding (Steijns et al., 2002).
The test range of the assay was 0.6–60 mg/L (coeﬃcient of variation
(CV) intra-assay: 0.8–2.8%, CV inter-assay: 2.9–6.5%).
Phenobarbital concentrations of the validation dataset (study 2)
were determined using a particle-enhanced turbidimetric inhibition
immunoassay (Petinia) on the Architect C4000 (Abbott Diagnostics;
Hoofddorp, The Netherlands) using Architect C4000 reagent system
cassettes at the pharmacy of the ErasmusMC, Rotterdam. The assay is
based on competition between drug in the sample and drug coated onto
a microparticle for antibody binding sites of the phenobarbital antibody
reagent. The test range is 2.0–80 mg/L (CV intra-assay: 0.9–4.8%, CV
inter-assay CV: 3.2–4.8%). A recent method comparing diﬀerent
immunoassays for phenobarbital found a Pearson correlation coeﬃ-
cient of 0.989 between a COBAS and an Architect system (Shipkova
et al., 2014).
2.4. Population pharmacokinetic analysis
The analysis was performed using NONMEM® version 7.3 (ICON
Development Solutions, Ellicott City, MD, USA), supported by Perl-
Table 1
Patient characteristics (median (range)) of the TDM dataset (study 1) and the prospective
validation dataset from the DINO study (study 2).
TDM data
(study 1)
Prospective data
(study 2)
Gestational age [weeks] 37 (24–42) 25 (24–31)
Birthweight [kg] 2.6 (0.45–4.4) 0.94 (0.58–2.2)
Postnatal age (at the day of inclusion) [days] 4.5 (0–22) 15 (1–76)
Duration on studya [days] 12 (4–85) 5 (1−20)
Actual bodyweight [kg] 2.7 (0.45–4.5) 1.07 (0.63–4.7)
APGAR-Score at 5 min 3 (0–9) 8 (1–9)
First Dose [mg/kg] 20 (4–40.7) 10.8 (2−22)
Maintenance Dose [mg/kg] 3.9 (1.3–20) 10.8 (1.2–20)
Samples after intravenous dosing [n] 226 56
Samples after oral dosing [n] 16 6
a Deﬁned as the time between the ﬁrst and the last blood sample contributing to the
analysis.
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speaks-NONMEM (PsN®) version 3.4.2 and Xpose version 4.3.5 (Keizer
et al., 2013). Model development started using the intravenous data.
After covariate inclusion and assessment of the model ﬁt, oral data was
added to the model. The absorption rate constant (ka) was ﬁxed to a
value of 50 h−1 obtained from literature (Grasela and Donn, 1985). The
ﬁrst-order conditional estimation with interaction method was used
throughout model development. In case of missing covariate informa-
tion for renal function or liver function, the last value observed in the
subject was carried forward. For actual bodyweight, linear interpola-
tion between available measurements was performed. The objective
function value was used to discriminate between nested models.
Standard errors obtained from NONMEM® and the conﬁdence intervals
of the bootstrap analysis in PsN® (n = 1000) were used to evaluate the
precision of the parameter estimates.
For the covariate analysis η-values (ETA) and conditional weighted
residuals (CWRES) were used. ETA values are deﬁned as the random
eﬀect describing the deviation of the individual empirical Bayes
estimate of the parameter from the typical population parameter
estimate of the corresponding parameter, e.g. CL or central volume of
distribution (V), for a given subject. Using the base model, plots of eta
values on CL and V versus covariates were used to investigate potential
covariates. In a next step potential covariates were evaluated using a
stepwise covariate modelling (SCM) procedure (Lindbom et al., 2005).
A signiﬁcance level of p≤ 0.05 was used for the forward inclusion and
a signiﬁcance level of ≤0.01 for the backward elimination.
2.5. Model evaluation
Key models as well as the ﬁnal model were evaluated using
goodness-of-ﬁt plots and normalized prediction distribution errors
(npde) (Comets et al., 2008) based on 1000 simulations of the model
and a bootstrap analysis based on 1000 samples of the data.
2.6. External model validation
Phenobarbital plasma concentrations from study 2 were predicted
by ﬁxing the parameters to the parameter estimates in the ﬁnal model
using post hoc Bayesian forecasting. To compare predicted and
observed values, goodness-of ﬁt was assessed and bias (mean prediction
error [MPE]) was calculated using Eq. (1):
MPE =
∑
n
100
predicted − observed
observed
∗
(1)
where n denotes number of observations. Predicted parameter values
were population predicted values for each individual.
2.7. Evaluation and optimization of dosing regimen
Based on the validated model (Krekels et al., 2011), the current
dosing regimen was critically reviewed for its ability to reach a target
concentration between 15 and 40 mg/L in all children. To this end,
1000 simulations of a child with a birthweight of 0.6, 1, 2 and 3 kg were
performed upon an intravenous loading dose of 20 mg/kg and an
intravenous maintenance dose of 5 mg/kg daily over 60 days. The
weight of the children born weighing 0.6, 1 and 2 kg was simulated to
develop according to the preterm growth curves published by Anchieta
et al. (2003) and the weight of child born weighing 3 kg was assumed to
develop as described by Thulier (2016).
In a next step the dosing regimen was modiﬁed in order to improve
target attainment in the simulated individuals.
Fig. 1. Clearance [L/h] versus postnatal age [days], depicted as population values (dashed lines) for children with a birthweight of 0.6 kg, 1 kg, 2 kg, 3 kg and 4 kg and individual posthoc
CL values (dots).
Table 2
Parameter estimates of the ﬁnal model and their corresponding bootstrap estimates.
Parameter Final model:
Estimate (RSE
%)
Bootstrap-estimate
(95% CI)
Fixed eﬀects
CL [L/h] = CLp 0.0091 (9%) 0.0092
(0.0072–0.011)
CLi = CLp ∗ (1 + ƟPNA ∗
(PNAi−Median)) ∗
(1 + ƟbBW ∗ (bBWi−Median))
ƟPNA [increase in CL per
postnatal day (PNA) (fraction)]
0.0533 (27%) 0.0523
(0.0201–0.0909)
ƟbBW [increase in CL per kg
birthweight (bBW) (fraction)]
0.369 (8%) 0.367 (0.319–0.414)
V [L] = Vp 2.38 (5%) 2.37 (2.16–2.63)
Vi = Vp ∗ (1 + ƟaBW ∗ (aBWi-
Median))
ƟaBW [increase in V per kg actual
bodyweight (aBW) (fraction)]
0.309 (8%) 0.309 (0.259–0.351)
50 FIX –
ka [h−1]
F [%]
59.4 (10%) 58.4 (30.5–80.0)
Inter-individual variability (eta)
On CL [%] 30.0 (29%) 28.7 (18.9–38.2)
On V [%] 22.4 (40%) 22.0 (12.7–30.1)
Residual variability
Proportional [%] 2.58 (22%) 2.55 (1.49–3.76)
CL = clearance, V = central volume of distribution, aBW = actual bodyweight,
bBW= birthweight, ka = absorption rate constant, F = bioavailability, median
PNA = 4.5 days; median bBW= 2.6 kg, median aBW= 2.7 kg, p = population mean
value of a parameter for an individual with PNA of 4.5 days and bBW of 2.6 kg.
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Fig. 2. Goodness-of-ﬁt plots of the model building (TDM data, study 1) (left panels) and the model validation (prospective data, study 2) (right panels, diamonds in e = outlying subject);
a/e: population predictions versus observed concentrations; b/f: individual predictions versus observed concentrations, c/g:conditional weighted residuals versus population prediction,
d/h: conditional weighted residuals versus time after ﬁrst dose.
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3. Results
3.1. Population pharmacokinetic model
Modelling of plasma concentrations resulted in a one compartment
model with intra-individual variability (IIV) on CL and V. A propor-
tional error yielded the best description of the residual variability.
Using this model without covariates, the plasma concentrations of the
smallest children were underpredicted and concentrations of the
heaviest children were overpredicted.
In the covariate analysis, birthweight, actual bodyweight, GA and
height showed high correlation coeﬃcients with CL, while only weak or
no correlations could be seen for Apgar scores, serum creatinine,
umbilical artery pH and PNA. V was highly correlated with birthweight,
actual bodyweight, GA and height. Other covariates showed weak
correlations. The stepwise covariate modelling proposed birthweight or
GA and PNA as predictors for CL and actual bodyweight as predictor of
V. No other covariates were found. Model ﬁt was comparable for the
combination of PNA and GA or PNA and birthweight on CL. In line with
the literature (De Cock et al., 2014) the model containing birthweight
and PNA on CL (Fig. 1) was carried forward as dosing based on
birthweight might lead to a more comprehensible dosing guideline. The
ETAs of the ﬁnal model showed no correlation to parameters relevant
for maturation and development indicating that covariates have been
correctly implemented (Supplement 1). Covariate inclusion reduced IIV
on CL and V from 56% to 30% and from 59% to 24%, respectively.
The ﬁnal parameter estimates as well as their respective bootstrap
estimate and conﬁdence interval (bootstrap convergence rate = 97.3%)
are displayed in Table 2. Bootstrap estimates are in good agreement
with the ﬁnal NONMEM® parameter estimates and show narrow
conﬁdence intervals for all structural parameters.
3.2. Model evaluation (study 1)
The model was able to suﬃciently describe the data of study 1 that
were used to build the model (Fig. 2, left panels). The npde-analysis
showed no trends towards a model misspeciﬁcation (Fig. 3).
3.3. External model validation (study 2)
Model validation with the external prospective dataset (study 2)
shows that the model can adequately predict the data of the included
infants without bias (Fig. 2, right panels). Only the peak concentrations
of one individual were underpredicted by the model (Fig. 2e, dia-
monds). The MPE was −8.4% corresponding to an adequate descrip-
tion of the data.
3.4. Evaluation and optimization of dosing regimen
According to the ﬁnal model, the current dosing regimen consisting
of an intravenous loading dose of 20 mg/kg and an intravenous
maintenance dose of 5 mg/kg/day resulted in distinct results in
children with diﬀerent birthweights (Fig. 4a). The ﬁgure shows that
the mean maximal plasma concentration (Cmax) after loading dose is
lower in smaller children. This is caused by a higher V [L/kg] in lighter
and thereby less mature children, leading to a lower Cmax following an
equal dose per kg bodyweight. After the loading dose the mean plasma
concentration of phenobarbital keeps increasing during the ﬁrst 10 days
of life. Thereafter a quasi-steady state concentration is reached for
about 5 days after which concentrations decrease over time due to the
model predicted maturation of CL with PNA (Fig. 1). At the same time
the percentage of simulations below the threshold of 15 mg/L increases.
Lower initial Cmax values in the smallest newborn result in the highest
proportion of subtherapeutic levels at the end of the observed period.
The current dosing regimen did not result in any concentrations above
the 40 mg/L within the 95% conﬁdence interval of 1000 simulations.
The highest concentrations were observed at a PNA of 10–15 days in
the simulations of a biggest child (birthweight = 3 kg). The lowest
concentrations were observed in the smallest child (birth-
weight = 0.6 kg) after 6–8 weeks.
When increasing the loading dose from 20 mg/kg to 30 mg/kg
(Fig. 4b), the therapeutic window is immediately reached for all
birthweights. If the maintenance dose is increased from 5 mg/kg/day
to 6 mg/kg/d at a PNA of 15 days, the simulated median plasma
concentration stays well in the desired target range (Fig. 4c).
4. Discussion
In this study, we successfully developed a population PK model for
phenobarbital in neonates on the basis of existing TDM data and
validated it with data from a prospective study. These results are of
particular importance as typically studies in (preterm) neonates are
complicated due to ethical and practical constraints which results in
frequent oﬀ-label use. The results of this study show that CL increases
with both birthweight and PNA (Fig. 1) while V is determined by actual
bodyweight (Table 2).
Besides providing new insights into the PK of phenobarbital in term
and preterm newborns this analysis highlights the advantages of data-
sharing. Only due to the utilization of TDM data from a previous study
(study 1) it was possible to develop a population pharmacokinetic
model for term and preterm newborns. The data from the DINO-study
(study 2) would have been insuﬃcient to build such a model as it only
contained data in infants born before 32 weeks of gestation. Covering
the whole age range helps at identifying maturational processes and
eventually aids dose ﬁnding. Furthermore, data sharing provided the
possibility of external validation with an independent dataset, however,
only in the very preterm age range. Due to the excellent ﬁt of the
validations data (Fig. 2) we do believe that our model is applicable for
the whole age range.
So far, only few population PK models of phenobarbital in neonates
Fig. 3. Numerical prediction distribution errors (npde) of the ﬁnal model: mean = 0.06501 (standard error = 0.063) and variance = 0.9018 (standard error = 0.084)).
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have been published. Yukawa et al. (2011) studied 70 neonates and
infants (GA: 24.1–43 weeks, PNA:1–73 days) and found that PNA and
total bodyweight were the dominant predictors of phenobarbital PK.
Furthermore, the authors observed and accounted for non-linearity in
the PK of phenobarbital at concentrations above 50 mg/L (Yukawa
et al., 2011). Data in dogs also indicate that auto-induction might be
present at very high doses resulting in concentrations outside the
therapeutic window (Abramson, 1988). As a possible mechanism
leading to non-linearity, auto-induction of phenobarbital metabolism
has been discussed in literature, even though it is anticipated to play a
minor role in adults (Nelson et al., 1982). Our analysis does not indicate
non-linearity, maybe due to the low number of concentrations above
50 mg/L that might have complicated discovering this trend. On the
other hand, it might as such not be relevant as non-linearity occurs
outside the therapeutic range of 15–40 mg/L.
Marsot et al. (2014) modelled phenobarbital data of 48 newborns
born at 27–42 weeks of gestation. Their covariate model is based on
allometric scaling with an exponent of three quarters on CL and a linear
exponent on V. Additional maturation of CL with PNA was not
observed. Based on simulations of the ﬁrst 12 days of life the authors
recommend an intravenous loading dose of 20 mg/kg in all neonates
and a weight-based maintenance dose. According to their advice, the
recommended maintenance dose decreases with increasing bodyweight
(Marsot et al., 2014). Our model as well as the model of Yukawa et al.
(2011) indicate that CL increases with PNA which would necessitate an
increased maintenance dose over the treatment course (Fig. 4). Based
on our simulation period of 60 days we propose that the maintenance
dose could be increased by 1 mg/kg at a PNA of 15 days to account for
this change.
Although information on the maturation of phenobarbital metabo-
lism in neonates is sparse, Boreus et al. (1978) showed that the
excretion of conjugated phenobarbital metabolite is signiﬁcantly re-
duced in newborns when compared to adults. In addition, phenobarbi-
tal is metabolized by Cytochrome P450, mainly through CYP2C9, with
minor metabolism by CYP2C19 and CYP2E1 (Paciﬁci, 2016). Peak
concentrations of one individual were slightly underpredicted by the
model. The C-reactive protein (CRP) in this child was elevated up to
100 mg/L. Literature suggests that inﬂammation as represented by high
CRP values might lead to a reduced function of Cytochrome P450 (CYP)
enzymes (Aitken et al., 2006). Reduced CYP activity might therefore
have resulted in elevated (peak) phenobarbital levels.
The CYP enzymes responsible for phenobarbital metabolism may be
subject to maturation processes (Bjorkman, 2006) and thereby explain
our ﬁndings. Ward et al. showed that the ontogeny of CYP2C19 has a
profound eﬀect on the weight-normalized CL of orally administered
pantoprazole. In their analysis, the CL of pantoprazole, another
CYP2C19 substrate, was positively correlated with PNA in 33 neonates
aged 1 to 19 days (Ward et al., 2010).
In line with these ﬁndings, Heimann et al. found a phenobarbital
half-life of 118.6 ± 16.1 h in term newborns (0–28 days) and a half-
life of 62.9 h ± 5.2 h in infants (1–12 months) using a classical two
stage approach (Heimann and Gladtke, 1977). Oztekin et al. observe
rapidly increasing phenobarbital trough levels during the ﬁrst four days
of life in very low birth weight infants (< 1500 g) (Oztekin et al.,
2013), which is in agreement with our results (Fig. 4). We can explain
these ﬁndings because of a very low CL, upon which steady-state is
reached after a long treatment period. Thus, instead of CL, V mainly
determines the PK proﬁle of phenobarbital during the ﬁrst week of life.
In view of these observations, we found high volumes of distribution
per kg bodyweight in newborns and thereby a high percentage of initial
plasma concentrations below the therapeutic range (Fig. 4). Our model
thus implies that neonates require higher loading doses than the
currently applied 20 mg/kg. Donn et al. investigated a higher loading
dose of 30 mg/kg in asphyxiated term newborns (Donn et al., 1985).
The mean observed plasma concentration 2 h after loading dose was
30.0 ± 3.2 mg/L and was not associated with an increased number of
side eﬀects. Safety data on higher loading doses in preterm newborns is
however lacking. Therefore, safety aspects should be evaluated when
administering higher loading doses in this vulnerable population.
Phenobarbital is the most frequently used treatment modality in
term newborns following asphyxia and whole body hypothermia
(Pokorna et al., 2015). In a recent evaluation Pokorna et al. (2015)
showed that the combination of asphyxia and hypothermia might have
an eﬀect on clearance of phenobarbital (personal communication).
Therefore, it might also be desirable to develop models for phenobar-
bital that can lead to optimized dosing in these conditions.
The results of the presented analysis indicate that the use of the
currently applied bodyweight based loading and maintenance dose of
phenobarbital in preterm newborns may have its limitations. Recent
observations from the population pharmacokinetic ﬁeld show that
bodyweight is often not the only determinant of the PK (Knibbe and
Danhof, 2011; Calvier et al., 2016). Our model as well as the model of
Yukawa et al. (2011) predict that maturation of CL is not related to
bodyweight alone but also to PNA. Therefore, preterm infants might
require adjusted dosing regimen correcting for this maturation.
The therapeutic window for phenobarbital remains a topic of
discussion. It might be possible that the therapeutic window in preterm
newborns diﬀers from that in term newborns, children or adults. To be
able to detect a potential age-dependent diﬀerence, phenobarbital
concentrations in the central nervous system would need to be linked
to eﬀect measures such as EEG or seizure frequency. Furthermore, the
eﬀect of concomitant medication was not tested in our study. It has, for
example, been demonstrated that co-medication with phenytoin or
valproate might lead to increased phenobarbital serum concentrations
(Paciﬁci, 2016). Thus, for subjects receiving these drugs other doses
than the ones recommended here might be suitable.
In conclusion, we strongly encourage data-sharing in the pediatric
and neonatal PK setting in order to use the data in an optimal fashion
and subsequently to minimize the burden on newborns. We show that
data-sharing can help to successfully develop and validate population
pharmacokinetic models in neonates. From the results it seems that for
phenobarbital both PNA and bodyweight are required to guide dosing
of phenobarbital in term and preterm neonates. Based on the presented
analysis the loading dose should be adjusted to 30 mg/kg in order to
immediately reach the therapeutic window and maintenance dose
should be increased by 1 mg/kg/day due at a PNA of 15 days due to
a maturation of CL with PNA.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ejps.2017.05.026.
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Fig. 4. Phenobarbital concentration time proﬁles (n = 1000) with blue line representing median and grey shaded areas 95% conﬁdence intervals for children with a birthweight of
0.6 kg, 1 kg, 2 kg and 3 kg (dashed red lines = therapeutic window) according to diﬀerent dosing regimens. a: current dosing regimen (i.v. loading dose: 20 mg/kg; i.v. maintenance dose:
5 mg/kg/day); b: increased i.v. loading dose (30 mg/mg), maintenance dose: 5 mg/kg/day; c: increased i.v. loading dose (30 mg/kg) and increased i.v. maintenance dose (6 mg/kg/day
vs. 5 mg/kg/day) starting at a PNA of 15 days. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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